Related references
Note: Only part of the references are listed.Cluster analysis-based clinical phenotypes of idiopathic interstitial pneumonias: associations with acute exacerbation and overall survival
Yoichiro Aoshima et al.
BMC PULMONARY MEDICINE (2021)
Pirfenidone in patients with progressive fibrotic interstitial lung diseases other than idiopathic pulmonary fibrosis (RELIEF): a double-blind, randomised, placebo-controlled, phase 2b trial
Juergen Behr et al.
LANCET RESPIRATORY MEDICINE (2021)
Baseline characteristics and survival of patients of idiopathic pulmonary fibrosis: a longitudinal analysis of the Swedish IPF Registry
Jing Gao et al.
RESPIRATORY RESEARCH (2021)
Pirfenidone in patients with unclassifiable progressive fibrosing interstitial lung disease: a double-blind, randomised, placebo-controlled, phase 2 trial
Toby M. Maher et al.
LANCET RESPIRATORY MEDICINE (2020)
A cluster-based analysis evaluating the impact of comorbidities in fibrotic interstitial lung disease
Alyson W. Wong et al.
RESPIRATORY RESEARCH (2020)
Modelling Forced Vital Capacity in Idiopathic Pulmonary Fibrosis: Optimising Trial Design
Eva Santermans et al.
ADVANCES IN THERAPY (2019)
Random forest-based imputation outperforms other methods for imputing LC-MS metabolomics data: a comparative study
Marietta Kokla et al.
BMC BIOINFORMATICS (2019)
Safety of nintedanib added to pirfenidone treatment for idiopathic pulmonary fibrosis
Kevin R. Flaherty et al.
EUROPEAN RESPIRATORY JOURNAL (2018)
IPF and CPFE - the two different entities or two different presentations of the same disease?
Sylwia Kwiatkowska
ADVANCES IN RESPIRATORY MEDICINE (2018)
Daily Home Spirometry: An Effective Tool for Detecting Progression in Idiopathic Pulmonary Fibrosis
Anne-Marie Russell et al.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE (2016)
Acute Exacerbation of Idiopathic Pulmonary Fibrosis An International Working Group Report
Harold R. Collard et al.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE (2016)
Nearest neighbor imputation algorithms: a critical evaluation
Lorenzo Beretta et al.
BMC MEDICAL INFORMATICS AND DECISION MAKING (2016)
Idiopathic Pulmonary Fibrosis Gender-Age-Physiology Index Stage for Predicting Future Lung Function Decline
Margaret L. Salisbury et al.
CHEST (2016)
Effect of continued treatment with pirfenidone following clinically meaningful declines in forced vital capacity: analysis of data from three phase 3 trials in patients with idiopathic pulmonary fibrosis
Steven D. Nathan et al.
THORAX (2016)
An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline: Treatment of Idiopathic Pulmonary Fibrosis An Update of the 2011 Clinical Practice Guideline
Ganesh Raghu et al.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE (2015)
Sensitivity Analyses of the Change in FVC in a Phase 3 Trial of Pirfenidone for Idiopathic Pulmonary Fibrosis
David J. Lederer et al.
CHEST (2015)
Missing data in IPF trials: do not let methodological issues undermine a major therapeutic breakthrough
Gabriel Thabut et al.
EUROPEAN RESPIRATORY JOURNAL (2015)
Change in forced vital capacity and associated subsequent outcomes in patients with newly diagnosed idiopathic pulmonary fibrosis
William M. Reichmann et al.
BMC PULMONARY MEDICINE (2015)
Longitudinal change in collagen degradation biomarkers in idiopathic pulmonary fibrosis: an analysis from the prospective, multicentre PROFILE study
R. Gisli Jenkins et al.
LANCET RESPIRATORY MEDICINE (2015)
A Phase 3 Trial of Pirfenidone in Patients with Idiopathic Pulmonary Fibrosis
Talmadge E. King et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Efficacy and Safety of Nintedanib in Idiopathic Pulmonary Fibrosis
Luca Richeldi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Neglected evidence in idiopathic pulmonary fibrosis: from history to earlier diagnosis
Jean-Francois Cordier et al.
EUROPEAN RESPIRATORY JOURNAL (2013)
Genetic variants associated with idiopathic pulmonary fibrosis susceptibility and mortality: a genome-wide association study
Imre Noth et al.
LANCET RESPIRATORY MEDICINE (2013)
Long-term Course and Prognosis of Idiopathic Pulmonary Fibrosis in the New Millennium
Steven D. Nathan et al.
CHEST (2011)
Pulmonary function measures predict mortality differently in IPF versus combined pulmonary fibrosis and emphysema
S. L. Schmidt et al.
EUROPEAN RESPIRATORY JOURNAL (2011)
Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials
Paul W. Noble et al.
LANCET (2011)
Clustering of the self-organizing map
J Vesanto et al.
IEEE TRANSACTIONS ON NEURAL NETWORKS (2000)
Share Paper
